Physician profile
Gary Helfin
NPI 1093739609
$6,679.09
in general payments reported to CMS, 2019-2025
31 companies · $450 in 2025
The $450 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $1,231 · 2021: $1,158 · 2022: $893 · 2023: $1,020 · 2024: $865 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,080.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $785.22 | 2019-2023 | |
| Lilly USA, LLC | $553.23 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Amgen INC. | $387.66 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $367.13 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $288.34 | 2019-2025 | Leqvio |
| Pfizer INC. | $281.94 | 2019-2025 | |
| Radius Health, INC. | $250.10 | 2019-2023 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $214.24 | 2019-2024 | Farxiga, Evusheld, Breztri |
| Exact Sciences Corporation | $195.74 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.11 | 2020-2025 | Jardiance |
| Astellas Pharma US INC | $137.19 | 2019-2022 | |
| Mylan Specialty L.P. | $123.76 | 2020-2024 | Yupelri |
| Abbvie INC. | $117.55 | 2022-2024 | |
| Amarin Pharma, INC. | $106.42 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $83.01 | 2021-2024 | |
| Glaxosmithkline, LLC. | $72.80 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Biogen, INC. | $54.85 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $51.83 | 2022-2023 | Quviviq |
| Allergan, INC. | $51.79 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $47.05 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $39.63 | 2021-2024 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $37.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $32.98 | 2020-2021 | |
| Edwards Lifesciences Corporation | $30.65 | 2025 | |
| Merck Sharp & Dohme LLC | $23.46 | 2020 | |
| Dexcom, INC. | $19.24 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.98 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.94 | 2021 | |
| Nevro Corp. | $15.52 | 2021 | |
| Phathom Pharmaceuticals, INC. | $14.38 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Helfin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.